FDA Gives Nod To Purdue Pharma New Formulation Of OxyContin
Purdue Pharma said that the drug is made to slowly release the potent opioid oxycodone to treat patients who require a continuous, around-the-clock opioid analgesic for management of
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
The pre-clinical data from earlier studies indicated enhanced immune responses against the malaria parasite (circumsporozoite stage of the Plasmodium falciparum) when Crucell’s Adenovirus (AdVac) technology and GSK’s RTS,S/AS